FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978344564> ?p ?o ?g. }

• W2978344564 endingPage "v496" @default.
• W2978344564 startingPage "v495" @default.
• W2978344564 abstract "Abstract Background HER2/neu is overexpressed in 15-25% of gastric cancer patients and associated with poor prognosis. Treatment with recombinant monoclonal Abs against HER2/neu is effective yet alternatives are needed due to cost and global availability issues. Thus a peptide vaccine (IMU-131) was developed, consisting of 3 fused B-cell epitopes (p467) from the HER2/neu extracellular domain coupled to CRM197 and administered with the adjuvant Montanide. The present study evaluated the optimal/safe vaccine dose leading to immunogenicity and clinical responses. Methods In an open-label multicenter Phase Ib trial (SE-Asia & Eastern Europe), 14 patients with HER2/neu overexpressing ( ++/ +++) gastric adenocarcinoma were recruited to receive 3 injections of IMU-131 (days 0, 14, 35) in combination with chemotherapy (CT). Dose escalation (10, 30 and 50 µg) was performed in 3 cohorts (C) to evaluate safety, immunogenicity and clinical responses. Results No SAEs related to IMU-131 administration were reported. Eleven patients were evaluable for vaccine-specific immune responses and RECIST assessment. Higher HER2-specific IgG levels were observed in C2 (30 µg) vs. C1 (10 µg). 3/5 patients in C2 showed moderate or little increase in HER2-specific Abs, while all C3 patients (50µg) responded with moderate to high Ab levels. According to RECIST, 1 patient showed complete response, 5 partial response and 4 stable disease. Strong correlation between high Ab levels and clinical responses was observed in C3, while this was only moderate in C2. Capacity to inhibit HER2 phosphorylation was tested in patient sera and could be detected in association with strong tumor reduction. Furthermore, patients with good clinical responses, but low Ab titers featured cellular responses with high IFNγ and TNFα/IL-10 ratios. Conclusions The vaccine was well tolerated and safe with Ab responses at the highest dose showing strong correlation with clinical responses. Currently, the 50 µg dose is being evaluated in a Phase II trial with two arms (IMU 131 + CT and CT only). Clinical trial identification NCT02795988. Legal entity responsible for the study Imugene Ltd. Funding Imugene Ltd. Disclosure U. Wiedermann: Research grant / Funding (institution), Officer / Board of Directors, CSO until September 2018: Imugene; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Themis. I. Bulat: Advisory / Consultancy, Research grant / Funding (self), Full / Part-time employment: Arensia Exploratory Medicine . T. Yau: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb. M. Maglakelidzde: Advisory / Consultancy, Research grant / Funding (self), Full / Part-time employment: ARENSIA Exploratory Medicine . T. Ungtrakul: Travel / Accommodation / Expenses: AstraZeneca. C.C. Zielinski: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy, Officer / Board of Directors, Scientific Advisory Board Member until June 2018: Imugene; Honoraria (self), Advisory / Consultancy: Ariad; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: Merrimack; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: KGaA; Honoraria (self), Advisory / Consultancy: Fibrogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Gilead; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Athenex. L. Chong: Honoraria (self), Advisory / Consultancy, Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Imugene Ltd. N. Ede: Leadership role, Research grant / Funding (institution), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Imugene Ltd. A. Good: Advisory / Consultancy, Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Imugene Ltd; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Kazia Therapeutics; Shareholder / Stockholder / Stock options: Living Cell Technologies. All other authors have declared no conflicts of interest." @default.
• W2978344564 created "2019-10-10" @default.
• W2978344564 creator A5000497968 @default.
• W2978344564 creator A5004447476 @default.
• W2978344564 creator A5004548381 @default.
• W2978344564 creator A5007216895 @default.
• W2978344564 creator A5019771742 @default.
• W2978344564 creator A5023630854 @default.
• W2978344564 creator A5026090288 @default.
• W2978344564 creator A5027932918 @default.
• W2978344564 creator A5028950420 @default.
• W2978344564 creator A5033329129 @default.
• W2978344564 creator A5035852624 @default.
• W2978344564 creator A5041880936 @default.
• W2978344564 creator A5048710316 @default.
• W2978344564 creator A5049829812 @default.
• W2978344564 creator A5052358350 @default.
• W2978344564 creator A5053390754 @default.
• W2978344564 creator A5077961608 @default.
• W2978344564 creator A5083271407 @default.
• W2978344564 creator A5087683383 @default.
• W2978344564 creator A5088826813 @default.
• W2978344564 date "2019-10-01" @default.
• W2978344564 modified "2023-10-02" @default.
• W2978344564 title "Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer" @default.
• W2978344564 doi "https://doi.org/10.1093/annonc/mdz253.038" @default.
• W2978344564 hasPublicationYear "2019" @default.
• W2978344564 type Work @default.
• W2978344564 sameAs 2978344564 @default.
• W2978344564 citedByCount "1" @default.
• W2978344564 countsByYear W29783445642020 @default.
• W2978344564 crossrefType "journal-article" @default.
• W2978344564 hasAuthorship W2978344564A5000497968 @default.
• W2978344564 hasAuthorship W2978344564A5004447476 @default.
• W2978344564 hasAuthorship W2978344564A5004548381 @default.
• W2978344564 hasAuthorship W2978344564A5007216895 @default.
• W2978344564 hasAuthorship W2978344564A5019771742 @default.
• W2978344564 hasAuthorship W2978344564A5023630854 @default.
• W2978344564 hasAuthorship W2978344564A5026090288 @default.
• W2978344564 hasAuthorship W2978344564A5027932918 @default.
• W2978344564 hasAuthorship W2978344564A5028950420 @default.
• W2978344564 hasAuthorship W2978344564A5033329129 @default.
• W2978344564 hasAuthorship W2978344564A5035852624 @default.
• W2978344564 hasAuthorship W2978344564A5041880936 @default.
• W2978344564 hasAuthorship W2978344564A5048710316 @default.
• W2978344564 hasAuthorship W2978344564A5049829812 @default.
• W2978344564 hasAuthorship W2978344564A5052358350 @default.
• W2978344564 hasAuthorship W2978344564A5053390754 @default.
• W2978344564 hasAuthorship W2978344564A5077961608 @default.
• W2978344564 hasAuthorship W2978344564A5083271407 @default.
• W2978344564 hasAuthorship W2978344564A5087683383 @default.
• W2978344564 hasAuthorship W2978344564A5088826813 @default.
• W2978344564 hasBestOaLocation W29783445641 @default.
• W2978344564 hasConcept C121608353 @default.
• W2978344564 hasConcept C126322002 @default.
• W2978344564 hasConcept C143998085 @default.
• W2978344564 hasConcept C159654299 @default.
• W2978344564 hasConcept C195616568 @default.
• W2978344564 hasConcept C203014093 @default.
• W2978344564 hasConcept C2776694085 @default.
• W2978344564 hasConcept C2776789287 @default.
• W2978344564 hasConcept C2777909004 @default.
• W2978344564 hasConcept C2778239845 @default.
• W2978344564 hasConcept C2780456651 @default.
• W2978344564 hasConcept C2780868878 @default.
• W2978344564 hasConcept C526805850 @default.
• W2978344564 hasConcept C71924100 @default.
• W2978344564 hasConcept C8891405 @default.
• W2978344564 hasConcept C98274493 @default.
• W2978344564 hasConceptScore W2978344564C121608353 @default.
• W2978344564 hasConceptScore W2978344564C126322002 @default.
• W2978344564 hasConceptScore W2978344564C143998085 @default.
• W2978344564 hasConceptScore W2978344564C159654299 @default.
• W2978344564 hasConceptScore W2978344564C195616568 @default.
• W2978344564 hasConceptScore W2978344564C203014093 @default.
• W2978344564 hasConceptScore W2978344564C2776694085 @default.
• W2978344564 hasConceptScore W2978344564C2776789287 @default.
• W2978344564 hasConceptScore W2978344564C2777909004 @default.
• W2978344564 hasConceptScore W2978344564C2778239845 @default.
• W2978344564 hasConceptScore W2978344564C2780456651 @default.
• W2978344564 hasConceptScore W2978344564C2780868878 @default.
• W2978344564 hasConceptScore W2978344564C526805850 @default.
• W2978344564 hasConceptScore W2978344564C71924100 @default.
• W2978344564 hasConceptScore W2978344564C8891405 @default.
• W2978344564 hasConceptScore W2978344564C98274493 @default.
• W2978344564 hasLocation W29783445641 @default.
• W2978344564 hasOpenAccess W2978344564 @default.
• W2978344564 hasPrimaryLocation W29783445641 @default.
• W2978344564 hasRelatedWork W13394025 @default.
• W2978344564 hasRelatedWork W2054100269 @default.
• W2978344564 hasRelatedWork W2363409655 @default.
• W2978344564 hasRelatedWork W2394853503 @default.
• W2978344564 hasRelatedWork W2406263212 @default.
• W2978344564 hasRelatedWork W2588595547 @default.
• W2978344564 hasRelatedWork W3088784163 @default.
• W2978344564 hasRelatedWork W3106560735 @default.
• W2978344564 hasRelatedWork W3121381120 @default.
• W2978344564 hasRelatedWork W363598932 @default.

• next